SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aurora Biosciences (ABSC)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Louis A. Rawden who wrote (164)9/29/1998 5:21:00 AM
From: Richard Haugland  Read Replies (2) of 359
 
Warner-Lambert Payment. The original agreement with W-L of September 23, 1997

aurorabio.com

called for about $25 million over 3 years (now ~1 year in). A more recent agreement with W-L on a compound storage system calls for about $9 million during the 15 months. I would anticipate the milestone payments to be back-end loaded so that most would be received toward the end of the contract as the major parts of the system fall into place but also there is probably an on-going payment for services performed.

Depending on the fraction of the milestone completed in yesterday's press announcement

biz.yahoo.com

this gives some idea of the limits of the payment. I would assume at least a few million $. Presumably it announcement yesterday means that this will be included in the revenues of the quarter ending this week and we may see more detail when that is reported. Support for the stock seems to be at only ~$4 yet but, IMO, could improve if revenues have improved this quarter. I believe the company must be going through a significant period of costs for development, however, given the number of on-going projects. It was not burning up money very fast previously relative to income.

I was at the Society for Biomolecular Screening meeting in Baltimore last week, which is the audience and technical forum for this field and was surprised by Aurora not having any visible presence in technical or marketing capacities, although at least one person from the company was there and some of this group interacts more one-to-one than through general interactions. Also, ABSC has limited their universe of companies with which they are dealing so they may feel that public exposure (and disclosure) is not warranted.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext